Close Menu

NEW YORK – A new study in advanced melanoma patients by researchers in Germany has found that tumor mutation burden (TMB), circulating tumor DNA (ctDNA), and cell-free DNA can predict response to combined immunotherapy and overall survival under the treatment.

In particular, treatment failure could be detected as early as three weeks after the start of therapy using ctDNA and cfDNA, which might help doctors and patients decide whether to continue treatment if adverse events occur early.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.


This webinar will address how two molecular laboratories are implementing tertiary analysis software to improve their precision oncology workflows.


This webinar will review how liquid biopsy can be considered as an alternative and non-invasive method to tissue biopsy for cancer molecular characterization.

Sponsored by

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  


This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.